Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that educational activities and numerous presentations describing the investigation of XIFAXAN
550mg/rifaximin will occur during The 63
Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). AASLD 2012, or The Liver Meeting
, is being held in Boston, MA, November 9-13, 2012.
Poster #P1548 Presidential Poster of Distinction
: Butterworth et al. “A critical flicker
frequency value of 32 Hz predicts recurrence of overt hepatic encephalopathy in a
double-blind, placebo controlled trial of rifaximin in patients with cirrhosis”
Bajaj et al. “Long-term use of rifaximin is associated with reduced
hospitalizations, prolonged remission: a placebo crossover analysis”
Ahluwalia et al. “The functional basis of improvement in inhibitory control in
minimal hepatic encephalopathy with rifaximin therapy”
Ahluwalia et al. “Rifaximin improves brain edema and working memory in
minimal hepatic encephalopathy: a prospective fMRI study”
: Neff et al. “Assessing treatment patterns in patients with overt hepatic
(rifaximin) 550 mg tablets
Important Safety Information
XIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age. In the trials of XIFAXAN for HE, 91 percent of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores greater than 25, and only 8.6 percent of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C).
XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema and anaphylaxis.